ClearVue Technologies (CPV) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
1 Nov, 2026Executive summary
Q1 FY27 marked a shift from technology validation toward commercial deployment, with product certifications, a binding Canva HQ subcontract and first Macau hotel testing of the LandVac window.
Gen 3 Vision Glass gained certifications enabling access to the EU and more than 50 markets; ClearVue-Helios rooftop panels joined Australia’s Clean Energy Council Approved Products List.
Financial highlights
Customer receipts were A$65,000; net cash used in operating activities was A$2.666m for the quarter.
Investing activities used A$194,000; financing activities generated net A$582,000, including A$1.255m equity proceeds and A$625,000 in borrowing repayments.
Cash and cash equivalents ended the quarter at A$2.281m, down from A$4.563m at the start of the period.
Outlook and guidance
Canva HQ balustrades, skylights and rooftop array covering ~660m² entered production; estimated annual generation is ~88,000 kWh, supporting the building’s target NABERS Energy rating.
Qatar University’s independent greenhouse trial will test energy generation, temperature, light transmission, cooling load and crop productivity; success could support future government greenhouse specifications.
Quarter-end funding was estimated at 1.3 quarters, based on A$2.281m cash and A$1.1m unused Riverfort capacity; future funding plans cite the ATM facility and prior capital raises.
Latest events from ClearVue Technologies
- Solar façades target a USD 183B serviceable market through an asset-light model.CPV
Investor presentation - Revenue declined and losses persisted, but global project wins and certifications position for growth.CPV
H2 2026 - Surpassed cost reduction targets, advanced BIPV innovation, and expanded global partnerships.CPV
Investor presentation - Cost reductions, certifications, and global pipeline growth drive commercial momentum.CPV
Investor update - Commercialisation accelerated with global sales, expanded product range, and increased funding.CPV
H2 2024 - Revenue up 528% year-over-year with global expansion and new partnerships fueling growth.CPV
H2 2025 - Net loss narrowed as restructuring and Gen3 rollout set stage for future growth.CPV
H1 2026 - Licensee growth, product advances, and cost cuts support commercialisation and funding.CPV
Q2 2026 TU - Operational progress and new certifications set to drive revenue growth and market expansion.CPV
Status update